Source: Patrys
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Patrys (PAB) receives $250,000 in funding to support its research on treatments for brain cancer
  • The Cure Brain Cancer Foundation allocated the funds to Patrys’ collaborator, Telethon Kids Institute
  • The money will be used to identify potential therapeutic applications of PAB’s PAT-DX1 and PAT-DX3 deoxymabs in the management and treatment of brain cancers
  • It will be used in both in vitro and in vivo models of high-grade glioma (HCG), with the deoxymabs to be used with standard of care (SOC) treatments
  • Shares are trading 4.76 per cent higher at 2.2 cents each just before market close

Patrys (PAB) has been awarded $250,000 in funding to support its research on potential treatments for brain cancer.

The Cure Brain Cancer Foundation allocated the funds to Patrys’ collaborator, Telethon Kids Institute.

The money will be used to identify potential therapeutic applications of PAB’s PAT-DX1 and PAT-DX3 deoxymabs in the management and treatment of brain cancers.

It will be used in both in vitro and in vivo models of high-grade glioma (HCG) — the most common and deadly type of brain cancer — with the deoxymabs to be used with standard of care (SOC) treatments.

The company believes this will block the repair of damaged DNA, resulting in an increase in cancer cell death.

The preclinical research program will be conducted at Telethon Kids Institute.

CEO and Managing Director Dr James Campbell said this is one of the company’s most exciting collaborations to date.

“We hope to grow our relationship with Cure Brain Cancer Foundation, and look forward
to expanding our connections to Australian brain cancer clinicians and researchers as we move towards our expected phase one clinical trial in mid-2023,” he said.

Shares were trading 4.76 per cent higher at 2.2 cents each at 4:03 pm AEST.

PAB by the numbers
More From The Market Herald

" Dimerix’s (ASX:DXB) DMX-700 study shows significant 80pc reduction in lung injury

Dimerix (ASX:DXB) has released its pipeline program DMX-700 study results which indicated a significant 80 per…

" Tesoro Gold (ASX:TSO) confirms El Zorro as a new Chilean Gold District

Tesoro Gold (ASX:TSO) has confirmed its El Zorro project as a new Chilean Intrusive Related Gold…
OncoSil Medical (ASX:OSL) - Managing Director & CEO, Nigel Lange

" Bupa UK becomes first insurance company to reimburse for OncoSil Medical’s (ASX:OSL) namesake device

Bupa UK Insurance has become the first health insurance company to provide reimbursement for OncoSil Medical's…

" Patrys (ASX:PAB) completes second engineering run for PAT-DX1

Biotech junior Patrys (ASX:PAB) has completed a second engineering run for its PAT-DX1 cancer antibody candidate…